Haloperidol blood levels and clinical outcome: A meta-analysis of studies relevant to testing the therapeutic window hypothesis

Journal of Clinical Pharmacy and Therapeutics

Volumn 21, Issue 4, 1996, Pages 229-236

  De Oliveira, I R ^a,b   De Sena, E P ^a,b   Pereira, E L A ^a   Miranda, A M A ^b   De Oliveira, N F ^a   Ribeiro, M G ^c   De Castro e Silva, E ^a   Dardennes, R M ^d   Samuel Lajeunesse, B ^d   Marcilio, C ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b Hlth Sec of the State of Bahia   (Brazil)

^c Rheumatology Division Centro Médico Do Hospital Aliança   (Brazil)

^d CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL;

ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; SCHIZOIDISM; SCHIZOPHRENIA;

EID: 10244222804     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.1996.tb01143.x     Document Type: Article

References (38)

1. Davis JM, Ericksen SE, Dekirmenjian H. (1978) Plasma levels of antipsychotic drugs and clinical response. In: Psychopharmacology: A Generation of Progress, eds Lipton MA, DiMascio A, Kilian KF. pp. 905-915. Raven Press, New York.
2. Bigelow LB, Kirch DG, Braun T, Korpi ER, Wagner AL, Zalcman S, Wyatt RJ. (1985) Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: A fixed-dose study. Psychopharmacology Bulletin, 21, 66-68.
3. Davis JM, Ericksen SE, Hurt S, Chang SS, Javaid JI, Dekirmenjian H, Casper R. (1985) Haloperidol plasma levels and clinical response: Basic concepts and clinical data. Psychopharmacology Bulletin, 21, 48-51.
4. De Oliveira IR, Dardennes RM, Amorim ES, Diquet B, de Sena EP, Moreira EC, de Castro e Silva E, Payan C, Fermanian J, Marcílio C, Samuel-Lajeunesse B. (1995) Is there a relationship between antipsychotic blood levels and their clinical efficacy? An analysis of studies design and methodology. Fundamental and Clinical Pharmacology, 9, 488-502.
5. Mavroidis ML, Kanter DR, Hirschowitz J, Carver DL. (1983) Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology, 81, 354-356.
6. Miller D, Hershey LA, Duffy JP, Abernethy DR, Greenblatt DJ. (1984) Serum haloperidol concentrations and clinical response in acute psychosis. Journal of Clinical Psychopharmacology, 4, 305-310.
7. Magliozzi JR, Hollister LE, Arnold KV, Earle GM. (1981) Relationship of serum haloperidol levels to clinical response in schizophrenic patients. American Journal of Psychiatry, 138, 365-367.
8. Coryell W, Kelly M, Perry PJ, Miller DD. (1990) Haloperidol plasma levels and acute clinical change in schizophrenia. Journal of Clinical Psychiatry, 10, 397-402.
9. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. (1987) Meta-analysis of randomized controlled trials. New England Journal of Medicine, 316, 450-455.
10. Poynard T, Conn HO. (1985) The retrieval of randomized clinical trials in liver disease from the medical literature: A comparison of MEDLARS and manual methods. Controlled Clinical Trials, 6, 271-279.
11. Bareta JC, Larson DB, Lyons JS, Zorc JJ. (1990) A comparison of manual and MEDLARS reviews of the literature on consultation-liaison psychiatry. American Journal of Psychiatry, 147, 1040-1042.
12. Bollini P, Pampallona S, Orza MJ, Adams ME, Chalmers TC. (1994) Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychological Medicine, 24, 307-316.
13. Astrachan BM, Harrow M, Adler D, Brauer L, Schwart A, Tucker G. (1972) A checklist for the diagnosis of schizophrenia. British Journal of Psychiatry, 121, 529-539.
14. Zelen M. (1971) The analysis of several 2 × 2 contingency tables. Biometrika, 58, 129-137.
15. Hosmer DW, Lemeshow S. (1989) Applied Logistic Regression. John Wiley & Sons, New York.
16. Potkin SG, Shen Y, Zhou D, Pardes H, Shu L, Phelps B, Poland R. (1985) Does a therapeutic window for plasma haloperidol exist? Preliminary Chinese data. Psychopharmacology Bulletin, 21, 59-61.
17. Van Putten T, Marder SR, May PRA, Poland RE, O'Brien RP. (1985) Plasma levels of haloperidol and clinical response. Psychopharmacology Bulletin, 21, 69-72.
18. Van Putten T, Marder SR, Mintz J, Poland R. (1988) Haloperidol plasma levels and clinical response: A therapeutic window relationship. Psychopharmacology Bulletin, 24, 172-175.
19. Van Putten T, Marder SR, Mintz J, Poland RE. (1992) Haloperidol plasma levels and clinical response: A therapeutic window relationship. American Journal of Psychiatry, 149, 500-505.
20. Smith RC, Vroulis G, Shvatsburd A, Allen R, Lewis N, Schoolar JC, Chojnacki M, Johnson R. (1982) RBC and plasma levels of haloperidol and clinical response in schizophrenia. American Journal of Psychiatry, 139, 1054-1056.
21. Smith RC, Baumgartner R, Schvartsburd A, Ravichandran GK, Vroulis G, Mauldin M. (1985) Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia. Psychopharmacology, 85, 449-455.
22. Santos JL, Cabranes JA, Almoguera I, Ramos JA, Vazquez C, Angeles F. (1989) Clinical implications of determination of plasma haloperidol levels. Acta Psychiatrica Scandinavica, 79, 348-354.
23. Santos JL, Cabranes JA, Vazquez C, Fuentenebro F, Almoguera I, Ramos JA. (1989) Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia. Biological Psychiatry, 26, 381-388.
24. Perry PJ, Pfohl BM, Kelly MW. (1988) The relationship of haloperidol concentrations to therapeutic response. Journal of Clinical Psychopharmacology, 8, 38-43.
25. Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M, Fowler J, Cooper TB. (1989) Dopamine receptor occupancy and plasma haloperidol levels. Archives of General Psychiatry, 46, 482-484.
26. Balant-Gorgia AE, Eisele R, Balant L, Garrone G. (1984) Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. European Archives of Psychiatry and Neurological Sciences, 234, 1-4.
27. Linkowski P, Hubain P, von Frenckell R, Mendlewicz J. (1984) Haloperidol plasma levels and clinical response in paranoid schizophrenics. European Archives of Psychiatry and Neurological Sciences, 234, 231-236.
28. Neborsky RJ, Janowsky DS, Perel JM, Munson E, Depry D. (1984) Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. Journal of Clinical Psychiatry, 45, 10-13.
29. Gerlach J, Behnke K, Heltberg J, Munk-Andersen E, Nielsen H. (1985) Sulpiride and haloperidol in schizophrenia: A double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. British Journal of Psychiatry, 147, 283-288.
30. Mavroidis ML, Garver DL, Kanter DR, Hirschowitz J. (1985) Plasma haloperidol levels and clinical response: Confounding variables. Psychopharmacology Bulletin, 21, 62-65.
31. Shostak M, Perel JM, Stiller RL, Wyman W, Curran S. (1987) Plasma haloperidol and clinical response: A role for reduced haloperidol in antipsychotic activity? Journal of Clinical Psychopharmacology, 7, 394-400.
32. Smith RC. (1987) Plasma haloperidol levels and clinical response. Archives of General Psychiatry, 44, 1110-1112.
33. Altamura C, Mauri M, Cavallaro F, Gorni A, Boreggi S. (1988) Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: Preliminary evidences. Progress in Neuropsychopharmacology and Biological Psychiatry, 12, 689-694.
34. Louzã-Neto MR, Müller-Spahn F, Rüther E, Scherer J. (1988) Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients. Pharmacopsychiatry, 21, 226-231.
35. Ko GN, Korpi ES, Kirch D. (1989) Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 9, 186-190.
36. Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, Gastanaga P, Krakowski M, Chou J, Crowner M, Douyon R. (1992) Haloperidol blood levels and clinical effects. Archives of General Psychiatry, 49, 354-361.
37. Mari JJ, Streiner DL. (1994) An overview of family interventions and relapse on schizophrenia: meta-analysis of research findings. Psychological Medicine, 24, 565-578.
38. Baldessarini RJ, Cohen BM, Teicher MH. (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry, 45, 79-91.